Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
33
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| O'Byrne Jason | CHIEF FINANCIAL OFFICER | 2 | $0 | $0 | 2026-09-01 |
| Harmon Cyrus | Director | 66 | $0 | $6.52M | 2026-07-24 |
| Raman Prakash | Director | 3 | $0 | $0 | 2026-06-18 |
| Hrustanovic Gorjan | Director | 10 | $0 | $0 | 2026-06-18 |
| Larson Yi | Director | 9 | $0 | $0 | 2026-06-18 |
| Graham G. Walmsley | Director | 30 | $54.66M | $44.36M | 2026-06-18 |
| Horning Sandra | Director | 8 | $0 | $0 | 2026-06-18 |
| Garland J. Scott | Director | 5 | $0 | $0 | 2026-06-18 |
| CLARK IAN T | Director | 20 | $0 | $7.87M | 2026-06-18 |
| LAMPERT MARK N | Director | 1 | $0 | $0 | 2026-06-18 |
| BUTITTA CYNTHIA M | Director | 11 | $0 | $0 | 2026-06-18 |
| RAPPAPORT ANDREW | Director | 18 | $0 | $0 | 2026-06-18 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | 10 | $0 | $951.5K | 2026-03-04 |
| Austin Sasha Lu | VP of Finance and Controller | 2 | $0 | $0 | 2026-02-02 |
| Zojwalla Naseem | Chief Medical Officer | 38 | $0 | $7.99M | 2026-02-02 |
| Bohen Sean | President and CEO | 39 | $0 | $2.11M | 2026-02-02 |
| Myles David C. | Chief Development Officer | 39 | $0 | $5.61M | 2026-02-02 |
| Kovacs Shane William Charles | Ch. Operating & Financial Off. | 26 | $0 | $3.57M | 2026-01-15 |
| BVF INC/IL | Director | 10 | $0 | $0 | 2025-06-11 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 3 | $1.73M | $0 | 2025-01-10 |
| BVF Partners OS Ltd. | Other | 7 | $0 | $0 | 2025-01-10 |
| Paradigm Biocapital Advisors LP | 10% Owner | 2 | $0 | $35.81M | 2024-08-01 |
| BVF II GP LLC | Director | 1 | $0 | $0 | 2024-06-14 |
| Paradigm BioCapital International Fund Ltd. | 10% Owner | 1 | $1.16M | $0 | 2023-12-06 |
| Biotechnology Value Trading Fund OS LP | Director | 6 | $15.62M | $0 | 2023-09-14 |
| BIOTECHNOLOGY VALUE FUND L P | Other | 4 | $6.95M | $0 | 2023-06-16 |
| Horn Kinney | Chief Business Officer | 46 | $0 | $2.98M | 2023-02-01 |
| Moriarty John B | EVP, Ch. Legal Officer & Sec. | 4 | $0 | $0 | 2023-02-01 |
| Kushner Peter J. | Chief Scientific Officer | 7 | $0 | $0 | 2022-02-01 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% Owner | 4 | $0 | $0 | 2020-11-23 |
| Cormorant Global Healthcare Master Fund, LP | 10% Owner | 4 | $8.07M | $0 | 2020-11-23 |
| MCCORMICK FRANK | Director | 6 | $0 | $0 | 2020-11-23 |
| BIOTECHNOLOGY VALUE FUND II LP | Other | 24 | $21.57M | $0 | 2020-11-19 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| O'Byrne Jason | CHIEF FINANCIAL OFFICER | A Award deriv | 2026-09-01 | 2026-09-02 | 650,000 | — | $0 | 650,000 | SEC↗ |
| O'Byrne Jason | CHIEF FINANCIAL OFFICER | A Award deriv | 2026-09-01 | 2026-09-02 | 650,000 | — | $0 | 650,000 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2026-07-24 | 2026-07-27 | 12,500 | $11.71 | $146.4K | 702,770 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2026-07-23 | 2026-07-27 | 12,500 | $11.58 | $144.8K | 715,270 | SEC↗ |
| Graham G. Walmsley | Director | A Award deriv | 2026-06-18 | 2026-06-23 | 29,500 | — | $0 | 29,500 | SEC↗ |
| RAPPAPORT ANDREW | Director | A Award deriv | 2026-06-18 | 2026-06-23 | 29,500 | — | $0 | 29,500 | SEC↗ |
| Raman Prakash | Director | A Award deriv | 2026-06-18 | 2026-06-23 | 29,500 | — | $0 | 29,500 | SEC↗ |
| Horning Sandra | Director | A Award deriv | 2026-06-18 | 2026-06-23 | 29,500 | — | $0 | 29,500 | SEC↗ |
| Larson Yi | Director | A Award deriv | 2026-06-18 | 2026-06-23 | 29,500 | — | $0 | 29,500 | SEC↗ |
| CLARK IAN T | Director | A Award deriv | 2026-06-18 | 2026-06-23 | 29,500 | — | $0 | 29,500 | SEC↗ |
| Hrustanovic Gorjan | Director | A Award deriv | 2026-06-18 | 2026-06-23 | 29,500 | — | $0 | 29,500 | SEC↗ |
| Garland J. Scott | Director | A Award deriv | 2026-06-18 | 2026-06-23 | 29,500 | — | $0 | 29,500 | SEC↗ |
| BUTITTA CYNTHIA M | Director | A Award deriv | 2026-06-18 | 2026-06-23 | 29,500 | — | $0 | 29,500 | SEC↗ |
| Harmon Cyrus | Director | A Award deriv | 2026-06-18 | 2026-06-23 | 29,500 | — | $0 | 29,500 | SEC↗ |
| LAMPERT MARK N | Director | A Award deriv | 2026-06-18 | 2026-06-23 | 29,500 | — | $0 | 29,500 | SEC↗ |
| Raman Prakash | Director | A Award deriv | 2026-04-28 | 2026-04-29 | 24,150 | — | $0 | 24,150 | SEC↗ |
| Raman Prakash | Director | A Award deriv | 2026-04-28 | 2026-04-29 | 2,911 | — | $0 | 2,911 | SEC↗ |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | M Exercise deriv | 2026-03-04 | 2026-03-05 | 25,000 | — | $0 | 410,000 | SEC↗ |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | S Sale | 2026-03-04 | 2026-03-05 | 24,767 | $24.25 | $600.6K | 233 | SEC↗ |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | M Exercise | 2026-03-04 | 2026-03-05 | 25,000 | $4.37 | $109.3K | 25,000 | SEC↗ |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | S Sale | 2026-03-04 | 2026-03-05 | 233 | $24.69 | $5.8K | 0 | SEC↗ |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | M Exercise deriv | 2026-03-03 | 2026-03-05 | 15,000 | — | $0 | 435,000 | SEC↗ |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | M Exercise | 2026-03-03 | 2026-03-05 | 15,000 | $4.37 | $65.5K | 15,000 | SEC↗ |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | S Sale | 2026-03-03 | 2026-03-05 | 15,000 | $23.01 | $345.1K | 0 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | A Award deriv | 2026-02-02 | 2026-02-04 | 275,000 | — | $0 | 275,000 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | A Award deriv | 2026-02-02 | 2026-02-04 | 850,000 | — | $0 | 850,000 | SEC↗ |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | A Award deriv | 2026-02-02 | 2026-02-04 | 220,000 | — | $0 | 220,000 | SEC↗ |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | A Award deriv | 2026-02-02 | 2026-02-04 | 56,250 | — | $0 | 56,250 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | A Award deriv | 2026-02-02 | 2026-02-04 | 106,250 | — | $0 | 106,250 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | A Award deriv | 2026-02-02 | 2026-02-04 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | A Award deriv | 2026-02-02 | 2026-02-04 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | A Award deriv | 2026-02-02 | 2026-02-04 | 106,250 | — | $0 | 106,250 | SEC↗ |
| Austin Sasha Lu | VP of Finance and Controller | A Award deriv | 2026-02-02 | 2026-02-17 | 29,250 | — | $0 | 29,250 | SEC↗ |
| Austin Sasha Lu | VP of Finance and Controller | A Award | 2026-02-02 | 2026-02-17 | 11,700 | — | $0 | 16,188 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2026-01-20 | 2026-01-21 | 10,000 | $26.88 | $268.8K | 727,770 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | S Sale | 2026-01-15 | 2026-01-15 | 100,000 | $28.73 | $2.87M | 139,727 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | M Exercise deriv | 2026-01-14 | 2026-01-14 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2026-01-14 | 2026-01-14 | 35,003 | $28.99 | $1.01M | 542,761 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2026-01-14 | 2026-01-14 | 14,997 | $28.60 | $428.9K | 577,764 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | M Exercise | 2026-01-14 | 2026-01-14 | 50,000 | $4.87 | $243.5K | 592,761 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2026-01-14 | 2026-01-16 | 3,489 | $29.12 | $101.6K | 737,770 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | M Exercise deriv | 2026-01-13 | 2026-01-14 | 50,000 | — | $0 | 100,000 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2026-01-13 | 2026-01-14 | 200 | $28.49 | $5.7K | 542,761 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2026-01-13 | 2026-01-14 | 49,800 | $27.60 | $1.37M | 542,961 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | M Exercise | 2026-01-13 | 2026-01-14 | 50,000 | $4.87 | $243.5K | 592,761 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | S Sale | 2026-01-13 | 2026-01-15 | 3,822 | $28.01 | $107.1K | 239,727 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2026-01-12 | 2026-01-14 | 10,000 | $28.34 | $283.4K | 144,846 | SEC↗ |
| Bohen Sean | President and CEO | G Gift | 2025-12-26 | 2025-12-30 | 8,500 | — | $0 | 237,650 | SEC↗ |
| Zojwalla Naseem | Chief Medical Officer | M Exercise deriv | 2025-12-23 | 2025-12-23 | 50,000 | — | $0 | 156,818 | SEC↗ |
| Zojwalla Naseem | Chief Medical Officer | M Exercise | 2025-12-23 | 2025-12-23 | 50,000 | $7.02 | $351.0K | 103,997 | SEC↗ |
| Zojwalla Naseem | Chief Medical Officer | S Sale | 2025-12-23 | 2025-12-23 | 99,509 | $27.66 | $2.75M | 4,488 | SEC↗ |
| Zojwalla Naseem | Chief Medical Officer | M Exercise deriv | 2025-12-22 | 2025-12-23 | 42,818 | — | $0 | 112,182 | SEC↗ |
| Zojwalla Naseem | Chief Medical Officer | M Exercise deriv | 2025-12-22 | 2025-12-23 | 7,182 | — | $0 | 206,818 | SEC↗ |
| Zojwalla Naseem | Chief Medical Officer | M Exercise | 2025-12-22 | 2025-12-23 | 7,182 | $7.02 | $50.4K | 153,997 | SEC↗ |
| Zojwalla Naseem | Chief Medical Officer | M Exercise | 2025-12-22 | 2025-12-23 | 42,818 | $15.25 | $653.0K | 146,815 | SEC↗ |
| Zojwalla Naseem | Chief Medical Officer | S Sale | 2025-12-22 | 2025-12-23 | 100,000 | $28.04 | $2.80M | 53,997 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2025-12-22 | 2025-12-29 | 2,881 | $28.53 | $82.2K | 741,259 | SEC↗ |
| Zojwalla Naseem | Chief Medical Officer | M Exercise deriv | 2025-12-19 | 2025-12-23 | 40,000 | — | $0 | 155,000 | SEC↗ |
| CLARK IAN T | Director | M Exercise deriv | 2025-12-19 | 2025-12-23 | 12,070 | — | $0 | 12,080 | SEC↗ |
| CLARK IAN T | Director | M Exercise deriv | 2025-12-19 | 2025-12-23 | 21,520 | — | $0 | 0 | SEC↗ |
| CLARK IAN T | Director | M Exercise deriv | 2025-12-19 | 2025-12-23 | 21,520 | — | $0 | 0 | SEC↗ |
| CLARK IAN T | Director | M Exercise deriv | 2025-12-19 | 2025-12-23 | 209,690 | — | $0 | 0 | SEC↗ |
| Zojwalla Naseem | Chief Medical Officer | S Sale | 2025-12-19 | 2025-12-23 | 12,921 | $28.93 | $373.8K | 103,997 | SEC↗ |
| Zojwalla Naseem | Chief Medical Officer | S Sale | 2025-12-19 | 2025-12-23 | 57,079 | $28.03 | $1.60M | 116,918 | SEC↗ |
| Zojwalla Naseem | Chief Medical Officer | M Exercise | 2025-12-19 | 2025-12-23 | 40,000 | $15.25 | $610.0K | 173,997 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2025-12-19 | 2025-12-23 | 1,225 | $28.08 | $34.4K | 601,656 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2025-12-19 | 2025-12-23 | 43,729 | $30.40 | $1.33M | 557,927 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2025-12-19 | 2025-12-23 | 6,046 | $31.39 | $189.8K | 551,881 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | G Gift | 2025-12-19 | 2025-12-23 | 9,000 | — | $0 | 542,881 | SEC↗ |
| CLARK IAN T | Director | S Sale | 2025-12-19 | 2025-12-23 | 41,840 | $30.48 | $1.28M | 0 | SEC↗ |
| CLARK IAN T | Director | S Sale | 2025-12-19 | 2025-12-23 | 193,056 | $29.71 | $5.74M | 41,840 | SEC↗ |
| CLARK IAN T | Director | S Sale | 2025-12-19 | 2025-12-23 | 29,904 | $28.83 | $862.1K | 234,896 | SEC↗ |
| CLARK IAN T | Director | M Exercise | 2025-12-19 | 2025-12-23 | 12,070 | $4.08 | $49.2K | 264,800 | SEC↗ |
| CLARK IAN T | Director | M Exercise | 2025-12-19 | 2025-12-23 | 21,520 | $7.84 | $168.7K | 252,730 | SEC↗ |
| CLARK IAN T | Director | M Exercise | 2025-12-19 | 2025-12-23 | 21,520 | $3.61 | $77.7K | 231,210 | SEC↗ |
| CLARK IAN T | Director | M Exercise | 2025-12-19 | 2025-12-23 | 209,690 | $4.41 | $924.7K | 209,690 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | G Gift | 2025-12-08 | 2025-12-09 | 75,000 | — | $0 | 243,549 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | G Gift | 2025-11-26 | 2025-12-01 | 225,000 | — | $0 | 318,549 | SEC↗ |
| RAPPAPORT ANDREW | Director | G Gift | 2025-11-25 | 2025-11-25 | 35,868 | — | $0 | 0 | SEC↗ |
| RAPPAPORT ANDREW | Director | M Exercise deriv | 2025-11-21 | 2025-11-25 | 35,868 | — | $0 | 0 | SEC↗ |
| RAPPAPORT ANDREW | Director | M Exercise | 2025-11-21 | 2025-11-25 | 35,868 | $0.39 | $14.0K | 35,868 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2025-09-18 | 2025-09-18 | 3,086 | $8.32 | $25.7K | 117,028 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2025-09-18 | 2025-09-18 | 10,000 | $8.33 | $83.3K | 744,140 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2025-09-16 | 2025-09-18 | 1,914 | $8.08 | $15.5K | 120,114 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2025-09-16 | 2025-09-18 | 10,000 | $8.04 | $80.4K | 754,140 | SEC↗ |
| RAPPAPORT ANDREW | Director | A Award deriv | 2025-06-11 | 2025-06-13 | 24,150 | — | $0 | 24,150 | SEC↗ |
| BUTITTA CYNTHIA M | Director | A Award deriv | 2025-06-11 | 2025-06-13 | 24,150 | — | $0 | 24,150 | SEC↗ |
| Harmon Cyrus | Director | A Award deriv | 2025-06-11 | 2025-06-13 | 24,150 | — | $0 | 24,150 | SEC↗ |
| Graham G. Walmsley | Director | A Award deriv | 2025-06-11 | 2025-06-13 | 24,150 | — | $0 | 24,150 | SEC↗ |
| Hrustanovic Gorjan | Director | A Award deriv | 2025-06-11 | 2025-06-13 | 24,150 | — | $0 | 24,150 | SEC↗ |
| CLARK IAN T | Director | A Award deriv | 2025-06-11 | 2025-06-13 | 24,150 | — | $0 | 24,150 | SEC↗ |
| Horning Sandra | Director | A Award deriv | 2025-06-11 | 2025-06-13 | 24,150 | — | $0 | 24,150 | SEC↗ |
| Garland J. Scott | Director | A Award deriv | 2025-06-11 | 2025-06-13 | 24,150 | — | $0 | 24,150 | SEC↗ |
| Larson Yi | Director | A Award deriv | 2025-06-11 | 2025-06-13 | 24,150 | — | $0 | 24,150 | SEC↗ |
| BVF INC/IL | Director | A Award deriv | 2025-06-11 | 2025-06-13 | 24,150 | — | $0 | 24,150 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | A Award deriv | 2025-02-28 | 2025-03-03 | 650,000 | — | $0 | 650,000 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | A Award deriv | 2025-02-28 | 2025-03-03 | 320,000 | — | $0 | 320,000 | SEC↗ |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | A Award deriv | 2025-02-28 | 2025-03-03 | 450,000 | — | $0 | 450,000 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | A Award deriv | 2025-02-28 | 2025-03-03 | 205,000 | — | $0 | 205,000 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | A Award deriv | 2025-02-28 | 2025-03-03 | 205,000 | — | $0 | 205,000 | SEC↗ |
| Bain Capital Life Sciences Inv | 10% Owner | J Other deriv | 2025-01-10 | 2025-01-13 | 3,500,000 | — | $0 | 3,500,000 | SEC↗ |
| BVF Partners OS Ltd. | Director | A Award deriv | 2025-01-10 | 2025-01-14 | 22,740 | — | $0 | 336,288 | SEC↗ |
| BVF Partners OS Ltd. | Director | A Award deriv | 2025-01-10 | 2025-01-14 | 235,450 | — | $0 | 3,291,004 | SEC↗ |
| BVF Partners OS Ltd. | Director | A Award deriv | 2025-01-10 | 2025-01-14 | 161,810 | — | $0 | 2,627,590 | SEC↗ |
| Bain Capital Life Sciences Inv | 10% Owner | J Other | 2025-01-10 | 2025-01-13 | 3,500,000 | — | $0 | 4,300,000 | SEC↗ |
| BVF Partners OS Ltd. | Director | D To issuer | 2025-01-10 | 2025-01-14 | 22,740 | — | $0 | 347,970 | SEC↗ |
| BVF Partners OS Ltd. | Director | D To issuer | 2025-01-10 | 2025-01-14 | 235,450 | — | $0 | 2,655,977 | SEC↗ |
| BVF Partners OS Ltd. | Director | D To issuer | 2025-01-10 | 2025-01-14 | 161,810 | — | $0 | 2,003,966 | SEC↗ |
| Bain Capital Life Sciences Inv | 10% Owner | P Buy | 2025-01-08 | 2025-01-13 | 300,000 | $5.76 | $1.73M | 7,800,000 | SEC↗ |
| Graham G. Walmsley | Director | S Sale | 2024-12-17 | 2024-12-17 | 700,761 | $6.75 | $4.73M | 0 | SEC↗ |
| Graham G. Walmsley | Director | P Buy | 2024-12-17 | 2024-12-17 | 700,761 | $6.75 | $4.73M | 1,408,875 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise deriv | 2024-12-16 | 2024-12-17 | 14,000 | — | $0 | 112,840 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise | 2024-12-16 | 2024-12-17 | 14,000 | $4.87 | $68.2K | 129,509 | SEC↗ |
| Graham G. Walmsley | Director | P Buy | 2024-12-13 | 2024-12-18 | 700,761 | $6.75 | $4.73M | 700,761 | SEC↗ |
| Graham G. Walmsley | Director | S Sale | 2024-12-13 | 2024-12-18 | 700,761 | $6.75 | $4.73M | 0 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | S Sale | 2024-12-11 | 2024-12-11 | 55,907 | $8.66 | $484.2K | 242,929 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | S Sale | 2024-12-11 | 2024-12-11 | 1,267 | $9.39 | $11.9K | 241,662 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | S Sale | 2024-12-11 | 2024-12-11 | 406 | $9.39 | $3.8K | 543,549 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | S Sale | 2024-12-11 | 2024-12-11 | 17,950 | $8.66 | $155.4K | 543,955 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | S Sale | 2024-12-11 | 2024-12-11 | 14,202 | $8.66 | $123.0K | 115,829 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | S Sale | 2024-12-11 | 2024-12-11 | 320 | $9.39 | $3.0K | 115,509 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2024-12-11 | 2024-12-11 | 13,314 | $8.66 | $115.3K | 598,633 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2024-12-11 | 2024-12-11 | 300 | $9.39 | $2.8K | 598,333 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-12-11 | 2024-12-11 | 179 | $9.39 | $1.7K | 764,140 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-12-11 | 2024-12-11 | 7,958 | $8.66 | $68.9K | 764,319 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | S Sale | 2024-12-10 | 2024-12-11 | 52,328 | $9.37 | $490.3K | 298,836 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | S Sale | 2024-12-10 | 2024-12-11 | 16,803 | $9.37 | $157.4K | 561,905 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | S Sale | 2024-12-10 | 2024-12-11 | 13,283 | $9.37 | $124.5K | 130,031 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2024-12-10 | 2024-12-11 | 12,452 | $9.38 | $116.8K | 611,947 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-12-10 | 2024-12-11 | 8,256 | $9.37 | $77.4K | 772,277 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | A Award | 2024-12-09 | 2024-12-11 | 204,750 | — | $0 | 351,164 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | A Award | 2024-12-09 | 2024-12-11 | 68,250 | — | $0 | 578,708 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | A Award | 2024-12-09 | 2024-12-11 | 52,000 | — | $0 | 143,314 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | A Award | 2024-12-09 | 2024-12-11 | 48,750 | — | $0 | 624,399 | SEC↗ |
| Harmon Cyrus | Director | A Award | 2024-12-09 | 2024-12-11 | 29,250 | — | $0 | 780,533 | SEC↗ |
| BVF INC/IL | Director | A Award deriv | 2024-12-04 | 2024-12-04 | 1,797,527 | — | $0 | 1,797,527 | SEC↗ |
| BVF INC/IL | Director | A Award deriv | 2024-12-04 | 2024-12-04 | 153,441 | — | $0 | 153,441 | SEC↗ |
| BVF INC/IL | Director | A Award deriv | 2024-12-04 | 2024-12-04 | 1,258,027 | $9.08 | $11.42M | 3,055,554 | SEC↗ |
| BVF INC/IL | Director | A Award deriv | 2024-12-04 | 2024-12-04 | 1,047,044 | $9.08 | $9.51M | 2,465,780 | SEC↗ |
| BVF INC/IL | Director | A Award deriv | 2024-12-04 | 2024-12-04 | 160,107 | $9.08 | $1.45M | 313,548 | SEC↗ |
| BVF INC/IL | Director | A Award deriv | 2024-12-04 | 2024-12-04 | 1,418,736 | — | $0 | 1,418,736 | SEC↗ |
| BVF INC/IL | Director | D To issuer | 2024-12-04 | 2024-12-04 | 153,441 | — | $0 | 370,710 | SEC↗ |
| BVF INC/IL | Director | D To issuer | 2024-12-04 | 2024-12-04 | 1,797,527 | — | $0 | 2,891,427 | SEC↗ |
| BVF INC/IL | Director | D To issuer | 2024-12-04 | 2024-12-04 | 1,418,736 | — | $0 | 2,165,776 | SEC↗ |
| Kovacs Shane William Charles | Ch. Operating & Financial Of | M Exercise deriv | 2024-11-15 | 2024-11-18 | 25,000 | — | $0 | 162,000 | SEC↗ |
| Kovacs Shane William Charles | Ch. Operating & Financial Of | M Exercise | 2024-11-15 | 2024-11-18 | 25,000 | $7.02 | $175.5K | 510,458 | SEC↗ |
| Paradigm Biocapital Advisors L | 10% Owner | S Sale | 2024-08-01 | 2024-08-05 | 1,870,499 | $14.92 | $27.91M | 4,720,482 | SEC↗ |
| Paradigm Biocapital Advisors L | 10% Owner | S Sale | 2024-08-01 | 2024-08-05 | 529,501 | $14.92 | $7.90M | 783,118 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-07-30 | 2024-07-31 | 934 | $15.55 | $14.5K | 751,283 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-07-29 | 2024-07-31 | 4,066 | $15.58 | $63.3K | 752,217 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-07-11 | 2024-07-12 | 5,000 | $12.26 | $61.3K | 756,283 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-06-28 | 2024-07-02 | 20,000 | $10.77 | $215.4K | 761,283 | SEC↗ |
| CLARK IAN T | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,000 | — | $0 | 23,000 | SEC↗ |
| BUTITTA CYNTHIA M | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,000 | — | $0 | 23,000 | SEC↗ |
| Garland J. Scott | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,000 | — | $0 | 23,000 | SEC↗ |
| Harmon Cyrus | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,000 | — | $0 | 23,000 | SEC↗ |
| Horning Sandra | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,000 | — | $0 | 23,000 | SEC↗ |
| Hrustanovic Gorjan | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,000 | — | $0 | 23,000 | SEC↗ |
| Larson Yi | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,000 | — | $0 | 23,000 | SEC↗ |
| RAPPAPORT ANDREW | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,000 | — | $0 | 23,000 | SEC↗ |
| Graham G. Walmsley | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,000 | — | $0 | 23,000 | SEC↗ |
| BVF II GP LLC | Director | A Award deriv | 2024-06-14 | 2024-06-18 | 23,000 | — | $0 | 23,000 | SEC↗ |
| Graham G. Walmsley | Director | S Sale | 2024-06-04 | 2024-11-26 | 700,000 | $14.85 | $10.39M | 700,761 | SEC↗ |
| Graham G. Walmsley | Director | S Sale | 2024-06-04 | 2024-11-26 | 475,000 | $14.85 | $7.05M | 708,114 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-06-04 | 2024-06-04 | 5,000 | $12.33 | $61.6K | 781,283 | SEC↗ |
| Graham G. Walmsley | Director | S Sale | 2024-06-04 | 2024-06-06 | 700,000 | $14.85 | $10.39M | 700,761 | SEC↗ |
| Graham G. Walmsley | Director | S Sale | 2024-06-04 | 2024-06-06 | 475,000 | $14.85 | $7.05M | 708,114 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-06-03 | 2024-06-04 | 5,000 | $10.93 | $54.6K | 786,283 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-05-31 | 2024-06-04 | 15,000 | $9.41 | $141.2K | 791,283 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise deriv | 2024-05-24 | 2024-05-28 | 9,460 | — | $0 | 126,840 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise | 2024-05-24 | 2024-05-28 | 9,460 | $4.87 | $46.1K | 89,824 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-05-06 | 2024-05-07 | 5,000 | $10.92 | $54.6K | 806,283 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-04-30 | 2024-05-02 | 15,000 | $9.51 | $142.7K | 811,283 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-03-28 | 2024-03-29 | 20,000 | $10.97 | $219.4K | 826,283 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise deriv | 2024-03-18 | 2024-03-20 | 13,700 | — | $0 | 136,300 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise | 2024-03-18 | 2024-03-20 | 13,700 | $4.87 | $66.7K | 80,364 | SEC↗ |
| RAPPAPORT ANDREW | Director | J Other | 2024-03-05 | 2024-03-06 | 481,014 | — | $0 | 0 | SEC↗ |
| RAPPAPORT ANDREW | Director | J Other | 2024-03-05 | 2024-03-06 | 385,965 | — | $0 | 385,965 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-02-29 | 2024-03-04 | 100 | $13.00 | $1.3K | 846,283 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-02-29 | 2024-03-04 | 24,900 | $12.41 | $309.0K | 846,383 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | A Award deriv | 2024-02-01 | 2024-02-05 | 621,500 | — | $0 | 621,500 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | A Award deriv | 2024-02-01 | 2024-02-05 | 304,500 | — | $0 | 304,500 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | A Award deriv | 2024-02-01 | 2024-02-05 | 195,000 | — | $0 | 195,000 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | A Award deriv | 2024-02-01 | 2024-02-05 | 195,000 | — | $0 | 195,000 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-02-01 | 2024-02-02 | 5,000 | $15.56 | $77.8K | 871,283 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2024-01-31 | 2024-02-02 | 25,000 | $12.23 | $305.8K | 876,283 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise deriv | 2024-01-25 | 2024-01-29 | 20,000 | — | $0 | 214,000 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise | 2024-01-25 | 2024-01-29 | 20,000 | $7.02 | $140.4K | 66,664 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | M Exercise deriv | 2024-01-12 | 2024-01-16 | 50,000 | — | $0 | 187,000 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | M Exercise | 2024-01-12 | 2024-01-16 | 50,000 | $7.02 | $351.0K | 484,987 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-12-29 | 2024-01-02 | 22,500 | $13.30 | $299.3K | 903,783 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-12-29 | 2024-01-02 | 2,500 | $14.10 | $35.3K | 901,283 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | M Exercise deriv | 2023-12-12 | 2023-12-12 | 10,000 | — | $0 | 237,000 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | M Exercise | 2023-12-12 | 2023-12-12 | 10,000 | $7.02 | $70.2K | 434,987 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise deriv | 2023-12-11 | 2023-12-12 | 2,900 | — | $0 | 234,000 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise | 2023-12-11 | 2023-12-12 | 2,900 | $7.02 | $20.4K | 46,664 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise deriv | 2023-12-06 | 2023-12-07 | 13,100 | — | $0 | 236,900 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | M Exercise | 2023-12-06 | 2023-12-07 | 13,100 | $7.02 | $92.0K | 43,764 | SEC↗ |
| Paradigm BioCapital Internatio | 10% Owner | P Buy | 2023-12-06 | 2023-12-08 | 100,000 | $11.60 | $1.16M | 6,590,981 | SEC↗ |
| Graham G. Walmsley | Director | P Buy | 2023-12-05 | 2023-12-18 | 31,870 | $14.73 | $469.4K | 1,700,000 | SEC↗ |
| Graham G. Walmsley | Director | P Buy | 2023-12-05 | 2023-12-18 | 50,000 | $14.95 | $747.5K | 1,750,000 | SEC↗ |
| Graham G. Walmsley | Director | P Buy | 2023-12-05 | 2023-12-18 | 50,000 | $13.09 | $654.5K | 1,800,000 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-11-30 | 2023-12-01 | 25,000 | $12.57 | $314.3K | 926,283 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | S Sale | 2023-11-22 | 2023-11-22 | 9,145 | $13.89 | $127.0K | 424,987 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | S Sale | 2023-11-22 | 2023-11-22 | 27,932 | $13.90 | $388.3K | 144,925 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-11-22 | 2023-11-22 | 3,989 | $13.90 | $55.4K | 951,283 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2023-11-22 | 2023-11-22 | 6,653 | $13.89 | $92.4K | 574,099 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | S Sale | 2023-11-22 | 2023-11-22 | 7,095 | $13.89 | $98.5K | 30,664 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | S Sale | 2023-11-21 | 2023-11-22 | 8,897 | $14.83 | $131.9K | 434,832 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | S Sale | 2023-11-21 | 2023-11-22 | 700 | $15.27 | $10.7K | 434,132 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | S Sale | 2023-11-21 | 2023-11-22 | 2,602 | $15.29 | $39.8K | 172,857 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | S Sale | 2023-11-21 | 2023-11-22 | 26,691 | $14.84 | $396.1K | 175,459 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-11-21 | 2023-11-22 | 4,192 | $14.86 | $62.3K | 955,272 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2023-11-21 | 2023-11-22 | 200 | $15.32 | $3.1K | 580,752 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2023-11-21 | 2023-11-22 | 6,776 | $14.87 | $100.8K | 580,952 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | S Sale | 2023-11-21 | 2023-11-22 | 200 | $15.33 | $3.1K | 37,759 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | S Sale | 2023-11-21 | 2023-11-22 | 7,261 | $14.83 | $107.7K | 37,959 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | A Award | 2023-11-20 | 2023-11-22 | 36,750 | — | $0 | 443,729 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | A Award | 2023-11-20 | 2023-11-22 | 110,250 | — | $0 | 202,150 | SEC↗ |
| Harmon Cyrus | Director | A Award | 2023-11-20 | 2023-11-22 | 15,750 | — | $0 | 959,464 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | A Award | 2023-11-20 | 2023-11-22 | 26,250 | — | $0 | 587,728 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | A Award | 2023-11-20 | 2023-11-22 | 28,000 | — | $0 | 45,220 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2023-11-08 | 2023-11-13 | 200 | $17.61 | $3.5K | 561,270 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2023-11-03 | 2023-11-03 | 541 | $17.51 | $9.5K | 561,470 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-11-02 | 2023-11-02 | 5,000 | $15.64 | $78.2K | 943,714 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2023-11-02 | 2023-11-03 | 3,332 | $15.36 | $51.2K | 562,011 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2023-11-01 | 2023-11-03 | 6,668 | $15.02 | $100.2K | 565,343 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-10-31 | 2023-11-02 | 25,000 | $12.05 | $301.3K | 948,714 | SEC↗ |
| Garland J. Scott | Director | A Award deriv | 2023-10-16 | 2023-10-17 | 14,347 | — | $0 | 14,347 | SEC↗ |
| Garland J. Scott | Director | A Award deriv | 2023-10-16 | 2023-10-17 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-09-29 | 2023-10-03 | 25,000 | $12.41 | $310.3K | 973,714 | SEC↗ |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV O | S Sale | 2023-09-19 | 2023-09-21 | 20,000 | $12.67 | $253.4K | 572,011 | SEC↗ |
| Biotechnology Value Trading Fu | Director | J Other | 2023-09-14 | 2023-09-14 | 99,556 | — | $0 | 99,556 | SEC↗ |
| Graham G. Walmsley | Director | P Buy | 2023-09-12 | 2023-12-18 | 508,130 | $9.84 | $5.00M | 1,668,130 | SEC↗ |
| Biotechnology Value Trading Fu | Director | P Buy | 2023-09-12 | 2023-09-14 | 677,853 | $9.84 | $6.67M | 3,584,512 | SEC↗ |
| Biotechnology Value Trading Fu | Director | P Buy | 2023-09-12 | 2023-09-14 | 52,801 | $9.84 | $519.6K | 524,151 | SEC↗ |
| Biotechnology Value Trading Fu | Director | P Buy | 2023-09-12 | 2023-09-14 | 775,278 | $9.84 | $7.63M | 4,688,954 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-09-05 | 2023-09-05 | 10,000 | $11.62 | $116.2K | 998,714 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-08-31 | 2023-09-05 | 15,000 | $9.36 | $140.4K | 1,008,714 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-08-16 | 2023-08-17 | 15,000 | $10.14 | $152.1K | 1,023,714 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-08-16 | 2023-09-05 | 15,000 | $10.14 | $152.1K | 1,023,714 | SEC↗ |
| RAPPAPORT ANDREW | Director | A Award deriv | 2023-06-16 | 2023-06-21 | 21,520 | — | $0 | 21,520 | SEC↗ |
| BUTITTA CYNTHIA M | Director | A Award deriv | 2023-06-16 | 2023-06-21 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Hrustanovic Gorjan | Director | A Award deriv | 2023-06-16 | 2023-06-21 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Graham G. Walmsley | Director | A Award deriv | 2023-06-16 | 2023-06-21 | 21,520 | — | $0 | 21,520 | SEC↗ |
| CLARK IAN T | Director | A Award deriv | 2023-06-16 | 2023-06-21 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Horning Sandra | Director | A Award deriv | 2023-06-16 | 2023-06-21 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Larson Yi | Director | A Award deriv | 2023-06-16 | 2023-06-21 | 21,520 | — | $0 | 21,520 | SEC↗ |
| BIOTECHNOLOGY VALUE FUND L P | Director | A Award deriv | 2023-06-16 | 2023-06-21 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-06-08 | 2023-06-09 | 10,000 | $6.30 | $63.0K | 1,038,714 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-06-06 | 2023-06-07 | 5,000 | $6.30 | $31.5K | 1,048,714 | SEC↗ |
| Harmon Cyrus | Director | S Sale | 2023-06-05 | 2023-06-07 | 5,000 | $6.05 | $30.3K | 1,053,714 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | P Buy | 2023-04-06 | 2023-04-07 | 10,000 | — | $0 | 396,197 | SEC↗ |
| Harmon Cyrus | Chief Research Officer | A Award deriv | 2023-02-01 | 2023-02-02 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Bohen Sean | President and CEO | A Award deriv | 2023-02-01 | 2023-02-02 | 550,000 | — | $0 | 550,000 | SEC↗ |
| Horn Kinney | Chief Business Officer | A Award deriv | 2023-02-01 | 2023-02-02 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Kovacs Shane William Charles | Ch. Operating & Financial Of | A Award deriv | 2023-02-01 | 2023-02-02 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Myles David C. | Chief Development Officer | A Award deriv | 2023-02-01 | 2023-02-02 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Moriarty John B | EVP, Ch. Legal Officer & Sec | A Award deriv | 2023-02-01 | 2023-02-02 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Zojwalla Naseem | Chief Medical Officer | A Award deriv | 2023-02-01 | 2023-02-02 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | A Award | 2022-09-21 | 2022-09-22 | 20,000 | — | $0 | 74,279 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | P Buy | 2022-09-21 | 2022-09-23 | 20,000 | — | $0 | 74,279 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | P Buy | 2022-09-02 | 2022-09-06 | 20,000 | — | $0 | 381,197 | SEC↗ |
| RAPPAPORT ANDREW | Director | A Award deriv | 2022-06-17 | 2022-06-27 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Hrustanovic Gorjan | Director | A Award deriv | 2022-06-17 | 2022-06-27 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Graham G. Walmsley | Director | A Award deriv | 2022-06-17 | 2022-06-27 | 21,520 | — | $0 | 21,520 | SEC↗ |
| BUTITTA CYNTHIA M | Director | A Award deriv | 2022-06-17 | 2022-06-27 | 21,520 | — | $0 | 21,520 | SEC↗ |
| CLARK IAN T | Director | A Award deriv | 2022-06-17 | 2022-06-27 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Horning Sandra | Director | A Award deriv | 2022-06-17 | 2022-06-27 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Larson Yi | Director | A Award deriv | 2022-06-17 | 2022-06-27 | 21,520 | — | $0 | 21,520 | SEC↗ |
| BUTITTA CYNTHIA M | Director | A Award deriv | 2022-06-16 | 2022-06-17 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Graham G. Walmsley | Director | A Award deriv | 2022-06-16 | 2022-06-17 | 21,520 | — | $0 | 21,520 | SEC↗ |
| RAPPAPORT ANDREW | Director | A Award deriv | 2022-06-16 | 2022-06-17 | 21,520 | — | $0 | 21,520 | SEC↗ |
| CLARK IAN T | Director | A Award deriv | 2022-06-16 | 2022-06-17 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Hrustanovic Gorjan | Director | A Award deriv | 2022-06-16 | 2022-06-17 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Horning Sandra | Director | A Award deriv | 2022-06-16 | 2022-06-17 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Larson Yi | Director | A Award deriv | 2022-06-16 | 2022-06-17 | 21,520 | — | $0 | 21,520 | SEC↗ |
| Biotechnology Value Trading Fu | Director | P Buy | 2022-06-10 | 2022-06-14 | 41,417 | $4.03 | $166.9K | 2,906,659 | SEC↗ |
| Biotechnology Value Trading Fu | Director | P Buy | 2022-06-10 | 2022-06-14 | 158,583 | $4.03 | $639.1K | 3,913,676 | SEC↗ |
| Horn Kinney | CHIEF BUSINESS OFFICER | M Exercise deriv | 2022-03-10 | 2022-03-14 | 5,253 | — | $0 | 141,785 | SEC↗ |
| Horn Kinney | CHIEF BUSINESS OFFICER | S Sale | 2022-03-10 | 2022-03-14 | 5,253 | $4.75 | $25.0K | 2,458 | SEC↗ |
| Horn Kinney | CHIEF BUSINESS OFFICER | M Exercise | 2022-03-10 | 2022-03-14 | 5,253 | $2.06 | $10.8K | 7,711 | SEC↗ |
| Horn Kinney | CHIEF BUSINESS OFFICER | M Exercise deriv | 2022-02-10 | 2022-02-14 | 5,251 | — | $0 | 147,038 | SEC↗ |
| Horn Kinney | CHIEF BUSINESS OFFICER | D To issuer | 2022-02-10 | 2022-02-14 | 5,251 | — | $0 | 2,458 | SEC↗ |
| Horn Kinney | CHIEF BUSINESS OFFICER | M Exercise | 2022-02-10 | 2022-02-14 | 5,251 | $2.06 | $10.8K | 7,709 | SEC↗ |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | A Award deriv | 2022-02-01 | 2022-02-03 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Bohen Sean | PRESIDENT AND CEO | A Award deriv | 2022-02-01 | 2022-02-03 | 812,250 | — | $0 | 812,250 | SEC↗ |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OF | A Award deriv | 2022-02-01 | 2022-02-03 | 247,000 | — | $0 | 247,000 | SEC↗ |
| Moriarty John B | EVP, CH. LEGAL OFFICER & SEC | A Award deriv | 2022-02-01 | 2022-02-03 | 166,250 | — | $0 | 166,250 | SEC↗ |
| Horn Kinney | CHIEF BUSINESS OFFICER | A Award deriv | 2022-02-01 | 2022-02-03 | 133,000 | — | $0 | 133,000 | SEC↗ |
| Harmon Cyrus | CHIEF TECHNOLOGY OFFICER | A Award deriv | 2022-02-01 | 2022-02-03 | 104,500 | — | $0 | 104,500 | SEC↗ |
| Kushner Peter J. | CHIEF SCIENTIFIC OFFICER | A Award deriv | 2022-02-01 | 2022-02-03 | 61,750 | — | $0 | 61,750 | SEC↗ |
| Myles David C. | CHIEF DEVELOPMENT OFFICER | A Award deriv | 2022-02-01 | 2022-02-03 | 118,750 | — | $0 | 118,750 | SEC↗ |
| Horn Kinney | CHIEF BUSINESS OFFICER | M Exercise deriv | 2022-01-10 | 2022-01-11 | 5,251 | — | $0 | 152,289 | SEC↗ |
| Horn Kinney | CHIEF BUSINESS OFFICER | S Sale | 2022-01-10 | 2022-01-11 | 5,251 | $6.85 | $36.0K | 2,458 | SEC↗ |
| Horn Kinney | CHIEF BUSINESS OFFICER | M Exercise | 2022-01-10 | 2022-01-11 | 5,251 | $2.06 | $10.8K | 7,709 | SEC↗ |
| Horn Kinney | CHIEF BUSINESS OFFICER | M Exercise deriv | 2021-12-10 | 2021-12-14 | 5,251 | — | $0 | 157,540 | SEC↗ |
| Myles David C. | CHIEF DEVELOPMENT OFFICER | S Sale | 2021-12-10 | 2021-12-14 | 10,000 | $10.30 | $103.0K | 582,901 | SEC↗ |
| Horn Kinney | CHIEF BUSINESS OFFICER | S Sale | 2021-12-10 | 2021-12-14 | 5,251 | $10.39 | $54.6K | 2,458 | SEC↗ |
| Horn Kinney | CHIEF BUSINESS OFFICER | M Exercise | 2021-12-10 | 2021-12-14 | 5,251 | $2.06 | $10.8K | 7,709 | SEC↗ |